Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
AstraZeneca
QuintilesIMS
Express Scripts
Johnson and Johnson
Healthtrust
McKinsey

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEBIVOLOL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Nebivolol Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00125853 The Effect of Nebivolol on Insulin Sensitivity Completed Foundation for Circulatory Health N/A The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.
NCT00125853 The Effect of Nebivolol on Insulin Sensitivity Completed Imperial College London N/A The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.
NCT00142584 Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension Completed Mylan Bertek Pharmaceuticals Phase 3 The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension
NCT00145210 Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans Completed Mylan Bertek Pharmaceuticals Phase 3 The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension.
NCT00145236 Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension Completed Mylan Bertek Pharmaceuticals Phase 3 The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension.
NCT00158093 A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo Completed Mylan Bertek Pharmaceuticals Phase 1 Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7.
NCT00200421 A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension Completed Mylan Bertek Pharmaceuticals Phase 2 The purpose of this study is to determine the effects on exercise capacity of nebivolol compared to atenolol in hypertensive patients.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nebivolol Hydrochloride

Condition Name

Condition Name for Nebivolol Hydrochloride
Intervention Trials
Hypertension 51
Heart Failure 5
Coronary Artery Disease 2
Erectile Dysfunction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nebivolol Hydrochloride
Intervention Trials
Hypertension 47
Heart Failure 7
Prehypertension 3
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nebivolol Hydrochloride

Trials by Country

Trials by Country for Nebivolol Hydrochloride
Location Trials
United States 304
Puerto Rico 3
Italy 3
United Kingdom 2
Korea, Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nebivolol Hydrochloride
Location Trials
Florida 16
Texas 16
Georgia 13
California 13
Tennessee 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nebivolol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Nebivolol Hydrochloride
Clinical Trial Phase Trials
Phase 4 38
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nebivolol Hydrochloride
Clinical Trial Phase Trials
Completed 52
Recruiting 7
Unknown status 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nebivolol Hydrochloride

Sponsor Name

Sponsor Name for Nebivolol Hydrochloride
Sponsor Trials
Forest Laboratories 39
Mylan Bertek Pharmaceuticals 9
Emory University 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nebivolol Hydrochloride
Sponsor Trials
Industry 61
Other 55
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Medtronic
Healthtrust
Chinese Patent Office
US Department of Justice
Johnson and Johnson
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.